Filing Flows › Ocular Therapeutix (OCUL) › Q1 2025
Ocular Therapeutix (OCUL) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 5, 2025
Ocular Therapeutix (OCUL) reported revenue of $10.7M for the first quarter 2025 (Q1 2025), -28% from a year earlier and -37% from the quarter before. Operating margin was -597.5%, net loss $64.1M (598.7% of revenue).
Ocular Therapeutix, Q1 2025: revenue $10.7M (-28% year over year), operating margin -597.5%, net loss $64.1M, operating cash flow −$44.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.7M | -37% | -28% |
| Operating profit | −$63.9M | — | — |
| Net earnings | −$64.1M | — | — |
| Operating cash flow | −$44.7M | — | — |
What changed
Revenue was $10.7M in Q1 2025, down 28% year over year and down 37% from the previous quarter. Product revenue, net was the largest line at 99% of revenue. Product revenue, net lost $4.1M year over year (down 28%), 100% of the total change.
Operating costs exceeded revenue by $63.9M, an operating margin of -597.5%. Total costs grew 61% against a revenue fall of 28%. The fastest-growing cost line was Research & development (+107%). The quarter ended with a net loss of $64.1M, wider than the previous quarter's $48.4M loss.
Operating cash flow was −$44.7M. Non-cash charges added back $1.0M of depreciation and amortization and $10.5M of share-based compensation. Working capital and other items added $7.9M. Capital expenditures of $1.9M exceeded it, leaving free cash flow of −$46.6M.
Questions
What was Ocular Therapeutix's revenue in the first quarter 2025?
Ocular Therapeutix (OCUL) reported revenue of $10.7M for the first quarter 2025 (Q1 2025), -28% from a year earlier and -37% from the quarter before.
Was Ocular Therapeutix profitable in the first quarter 2025?
Operating loss was $63.9M (-597.5% of revenue) and net loss $64.1M.
Source: Ocular Therapeutix 10-Q on SEC EDGAR.